Related Experiment Video

Updated: Sep 12, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

630

Impaired Secondary Platelet Response in Chronic Kidney Disease as a Consequence of Prior Platelet Activation

Constance C F M J Baaten1, Julia Wollenhaupt2, Tobias M Henning2

  • 1Institute for Molecular Cardiovascular Research (IMCAR), University Hospital RWTH Aachen, Aachen, Germany; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands; Aachen-Maastricht Institute for Cardiorenal disease (AMICARE), Aachen, Germany.

JACC. Basic to Translational Science
|August 6, 2025
PubMed

Insights

Patients with chronic kidney disease (CKD) exhibit platelet preactivation and dysfunction. Acetylsalicylic acid (ASA) treatment may mitigate these platelet issues in CKD patients and mice.

Area of Science:

  • Nephrology
  • Hematology
  • Translational Medicine

Background:

  • Chronic kidney disease (CKD) patients face higher risks of bleeding and clotting.
  • Existing research on platelet defects in CKD presents conflicting findings.

Purpose of the Study:

  • To investigate platelet function in advanced CKD patients and a CKD mouse model.
  • To compare platelet function in CKD patients with and without acetylsalicylic acid (ASA) therapy.

Main Methods:

  • Examined platelet function in CKD stages 3-5 dialysis patients (without antithrombotic therapy).
  • Assessed platelet function in CKD stage 5 dialysis (CKD5D) patients on ASA.
  • Utilized a CKD mouse model to study platelet behavior with and without ASA.

Main Results:

  • CKD patients without antithrombotic therapy showed platelet preactivation and partial secondary dysfunction, particularly upon collagen/GPVI stimulation.
  • Hemodialysis patients on ASA displayed less severe CKD-associated platelet dysfunction compared to non-ASA users.
  • Similar protective effects of ASA on platelet function were observed in the CKD mouse model.

Conclusions:

  • Advanced CKD is associated with platelet preactivation and dysfunction.
  • ASA treatment appears to ameliorate CKD-related platelet dysfunction in both human patients and a preclinical mouse model.

Keywords:
acetylsalicylic acidbleedingchronic kidney diseaseplateletsthrombosis

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

19.9K

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
93
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
68
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
76
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
80
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
94